Lanifibranor

Explore the latest developments and research regarding Lanifibranor, a promising pan-PPAR agonist under investigation for the treatment of NASH.

A brief introduction to the most promising pharmacological agents for NASH

Authors: Ratziu V and Tacke F
Published in Journal of Hepatology (July 2023)
The last decade has seen an unprecedented amount of data in the way of therapeutic research for non-alcoholic steatohepatitis (NASH), the progressive form of non-alcoholic fatty liver disease (NAFLD).
Read MoreA brief introduction to the most promising pharmacological agents for NASH

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES